

## RSV vaccines - CDC Advisory Committee on Immunization Practices update

- On June 21, 2023, the CDC's <u>Advisory Committee on Immunization Practices (ACIP) voted to recommend</u> that adults aged 60 years and older may receive a single dose of a respiratory syncytial virus (RSV) vaccine, using <u>shared clinical decision-making based on risk assessment</u>.
  - In May 2023, the FDA approved the first two RSV vaccines for adults aged 60 years and older: GSK's <u>Arexvy™ (respiratory syncytial virus vaccine, adjuvanted)</u> and Pfizer's Abrysvo™ (respiratory syncytial virus vaccine).
- Unlike routine, catch-up, and risk-based recommendations, shared clinical decision-making vaccinations are not recommended for everyone in a particular age group or everyone in an identifiable risk group. Shared clinical decision-making recommendations are individually based and informed by a decision process between the health care provider and the patient.
  - For routine, catch-up, and risk-based recommendations, the default decision should be to vaccinate the patient based on age group or other indication, unless contraindicated.
  - For shared clinical decision-making recommendations, the decision about whether or not to vaccinate may be informed by the best available evidence of who may benefit from vaccination; the individual's characteristics, values, and preferences; the health care provider's clinical discretion; and the characteristics of the vaccine being considered.
- The ACIP recommendations will be forwarded to the CDC director and the Department of Health and Human Services for review and approval.
  - Once approved, the final recommendations will be published in a future Morbidity and Mortality Weekly Report (MMWR) to advise healthcare providers.
- At the ACIP meeting, GSK said it expects to price its vaccine between \$200 and \$295 per dose. Pfizer provided a price range of \$180 to \$270 per dose.
- It is expected that both Arexvy and Abrysvo will be available in time for the next RSV season, which is normally in the winter.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.